Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: A review

International Journal of Cardiovascular Interventions

Volumn 5, Issue 1, 2003, Pages 27-34

  Kusumanto, Y H ^a   Hospers, G A P ^a,b   Mulder, N H ^a   Tio, R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Clinical studies; Gene therapy; Ischaemic tissue disease; Therapeutic angiogenesis; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ARTERY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GENE; GENE THERAPY; GENE TRANSFER; HUMAN; ISCHEMIA; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TELANGIECTASIA; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VASCULAR SURGERY;

ANIMALS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RABBITS; SAFETY; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037284014     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/14628840304612     Document Type: Review

References (94)

1. Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. Arch Intern Med 1991; 151: 2373-2382.
2. Carbajal EV, Deedwania PC. Silent ischemia: mechanisms, diagnosis, and prevalence. Prim Cardiol 1991; 17: 30-40.
3. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
4. Schainfeld RM, Isner JM. Critical limb ischemia: nothing to give at the office? Ann Intern Med 1999; 130: 442-444.
5. Isner JM. Manipulating angiogenesis against vascular disease. Hosp Pract (Off Ed) 1999; 34: 69-74, 76, 79-80 passim.
6. Folkman J. Angiogenic therapy of the human heart. Circulation 1998; 97: 628-629.
7. Bauters C. Growth factors as a potential new treatment for ischemic heart disease. Clin Cardiol 1997; 20(suppl 2): II-52-II-57.
8. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3: 158-164.
9. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 2000; 190: 338-342.
10. Beck L Jr., D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997; 11: 365-373.
11. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
12. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964-3972.
13. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13: 1055-1066.
14. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
15. Jain RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998; 95: 10820-10825.
16. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-1598.
17. Kamiya A, Togawa T. Adaptive regulation of wall shear stress to flow change in the canine carotid artery. Am J Physiol 1980; 239: H14-21.
18. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
19. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-449.
20. Bauters C, Asahara T, Zheng LP et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314-324.
21. Tsurumi Y, Takeshita S, Chen D et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.
22. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A: 2413-2422.
23. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999; 253: 117-130.
24. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
25. Connolly DT, Olander JV, Heuvelman D et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264: 20017-20024.
26. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
27. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
28. Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000; 20: 1512-1520.
29. Servos S, Zachary I, Martin JF. VEGF modulates NO production: the basis of a cytoprotective effect? Cardiovasc Res 1999; 41: 509-510.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
31. Plouet J, Moro F, Bertagnolli S et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-13396.
32. Neufeld G, Cohen T, Gitay-Goren H et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996; 15: 153-158.
33. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
34. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270: 19761-19766.
35. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994; 90: 649-652.
36. Ramos MA, Kuzuya M, Esaki T et al. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1998; 18: 1188-1196.
37. Li J, Perrella MA, Tsai JC et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995; 270: 308-312.
38. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343.
39. Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-17634.
40. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res 1998; 83: 832-840.
41. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A 1996; 93: 1988-1992.
42. Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-298.
43. Hewett PW, Murray JC. Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 1996; 221: 697-702.
44. Takeshita S, Pu LQ, Stein LA et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90 (5 Pt 2): II-228-II-34.
45. Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-2189.
46. Bauters C, Asahara T, Zheng LP et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 1994; 267(4 Pt 2): H1263-H1271.
47. Lopez JJ, Laham RJ, Stamler A et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998; 40: 272-281.
48. Hariawala MD, Horowitz JR, Esakof D et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63: 77-82.
49. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 1993; 4: 749-758.
50. Takeshita S, Weir L, Chen D et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227: 628-635.
51. Feldman LJ, Steg PG, Zheng LP et al. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995; 95: 2662-2671.
52. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
53. Losordo DW, Pickering JG, Takeshita S et al. Use of the rabbit ear artery to serially assess foreign protein secretion after site-specific arterial gene transfer in vivo. Evidence that anatomic identification of successful gene transfer may underestimate the potential magnitude of transgene expression. Circulation 1994; 89: 785-792.
54. Tsurumi Y, Takeshita S, Chen D et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.
55. Tio RA, Tkebuchava T, Scheuermann TH et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999; 10: 2953-2960.
56. Witzenbichler B, Asahara T, Murohara T et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381-394.
57. Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-670.
58. Isner JM, Walsh K, Symes J et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 1996; 7: 959-988.
59. Takeshita S, Rossow ST, Kearney M et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649-1660.
60. Sundberg C, Nagy JA, Brown LF et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001; 158: 1145-1160.
61. Henry TD, Rocha-Singh K, Isner JM et al. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial. J Am Coll Cardiol 1998; 31: 65A.
62. Gibson CM, Laham RJ, Giordano FJ et al. Magnitude and location of new angiographically apparent coronary collateral following intravenous VEGF administration. J Am Coll Cardiol 1999; 33: 384A.
63. Henry TD, Annex BH, Azrin MA et al. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - the VIVA trial. J Am Coll Cardiol 1999; 33(suppl A): 38A (abstr).
64. Henry TD, Annex BH, Azrin M et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 1999; 100(18): 1-476.
65. Isner JM, Pieczek A, Schainfeld R et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374.
66. Isner JM, Baumgartner I, Rauh G et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973.
67. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
68. Simovic D, Isner JM, Ropper AH, Pieczek A, Weinberg DH. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-768.
69. Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
70. Rosengart TK, Lee LY, Patel SR et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474.
71. Lathi KG, Vale PR, Losordo DW et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001; 92: 19-25.
72. Vale PR, Losordo DW, Milliken CE et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-2143.
73. Vale PR, Losordo DW, Milliken CE et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-974.
74. Tio RA, Tan ES, de Fong R, Pruim J, van Boven AJ. Myocardial gene therapy with vascular endothelial growth factor (VEGF) and not endomyocardial laser therapy improves perfusion reserve in patients with end stage coronary artery disease (CAD). Circulation 2001; 104: 264.
75. Rauh G, Gravereaux E, Pieczed A, Curry C, Schainfeld R, Isner JM. Assessment of safety and efficiency of intramuscular gene therapy with VEGF-2 in patients with critical limb ischaemia. Circulation 1999; 100: 1-770.
76. Kusumanto YH, Mulder NH, Dullaart RPF et al. Phase III comparison of intramuscular delivery of ANG1 (a vascular endothelial growth factor containing plasmid) with placebo in diabetic patients with critical limb ischaemia. Mol Ther 2001; 3: S73.
77. Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001; 89: 389-400.
78. Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
79. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429.
80. Baumgartner I, Rauh G, Pieczek A et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-884.
81. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
82. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-1598.
83. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 07(6801): 242-248.
84. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-521.
85. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-831.
86. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69: 508-517.
87. Asahara T, Bauters C, Zheng LP et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92(9 suppl): II-365-II-371.
88. Peters KG. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 1998; 83: 342-343.
89. Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-463.
90. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277(5322): 55-60.
91. Van Belle E, Rivard A, Chen D et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96: 2667-2674.
92. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-363.
93. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102: 185-190.
94. Semenza GL. Hypoxia-inducible factor 1: master regulator of 02 homeostasis. Curr Opin Genet Dev 1998; 8: 588-594.